| human | Q5 |
| P2798 | Loop ID | 195436 |
| P496 | ORCID iD | 0000-0001-6666-7244 |
| P11725 | PubliCatt author ID | 04243 |
| P1153 | Scopus author ID | 26538821100 |
| P9914 | USiena air author ID | 111066 |
| P734 | family name | Plantone | Q100699351 |
| Plantone | Q100699351 | ||
| Plantone | Q100699351 | ||
| P735 | given name | Domenico | Q1765453 |
| Domenico | Q1765453 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q61448811 | A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis |
| Q99717167 | A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis |
| Q40355459 | Acute necrotizing encephalopathy during novel influenza A (H1N1) virus infection. |
| Q87797913 | Acute refractory intestinal pseudo-obstruction in MELAS: efficacy of prucalopride |
| Q62580283 | Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis |
| Q85338079 | Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders |
| Q61899281 | Association between Anemia and Multiple Sclerosis |
| Q48157809 | Brain perfusion by arterial spin labeling MRI in multiple sclerosis. |
| Q82477722 | Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer |
| Q82991767 | CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment |
| Q82813050 | CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients |
| Q44025134 | Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. |
| Q54700804 | Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis. |
| Q92585708 | Clinical and MRI Predictors of Conversion From Mild Behavioural Impairment to Dementia |
| Q37472186 | Commentary: Tumefactive Demyelinating Lesions as a First Clinical Event: Clinical, Imaging, and Follow-up Observations. |
| Q28389257 | Concurrence of multiple sclerosis and brain tumors |
| Q36181062 | Copper deficiency myelopathy: A report of two cases. |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q35211902 | Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. |
| Q37027689 | Dimethyl fumarate may still have a role in progressive multiple sclerosis. |
| Q85257825 | Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations |
| Q34781691 | Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. |
| Q56264476 | Focal Hyperhidrosis in Tumefactive Multiple Sclerosis |
| Q36369640 | Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis |
| Q40608676 | HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence |
| Q48013153 | Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment. |
| Q33424731 | Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients |
| Q40324994 | Involvement of type I immune responses in swine-origin H1N1 influenza virus infection. |
| Q86885261 | Midbrain panda sign in a patient with Wilson's disease |
| Q101383041 | NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study |
| Q86517437 | Osteoma of the internal auditory canal |
| Q86552745 | PPIs as possible risk factor for copper deficiency myelopathy |
| Q37287991 | Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report |
| Q46427580 | Paroxysmal ataxia and dysarthria in multiple sclerosis. |
| Q89397480 | Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview |
| Q85592468 | Resolution of muscle inflammation after tumor removal in a woman with paraneoplastic dermatomyositis |
| Q85995977 | Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab |
| Q38831720 | Secondary Progressive Multiple Sclerosis: Definition and Measurement. |
| Q50870839 | Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. |
| Q59330197 | Striatum Involvement in LGI1 Limbic Encephalitis |
| Q47336747 | Systematic assessment and characterization of chronic pain in multiple sclerosis patients. |
| Q43967781 | T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. |
| Q59891056 | THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MS – CURRENT UPDATE |
| Q48610807 | The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy |
| Q92132284 | Tumefactive Demyelinating Lesions and Pregnancy |
| Q84186595 | Type 1 immune response in progressive multiple sclerosis |
Search more.